Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.

Neoplasia (New York, N.Y.)·2026
Same author

Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Current problems in cancer·2026
Same author

Development and optimization of host DNA depletion in blood cultures using a saponin and salt-activated nuclease-based method.

Frontiers in microbiology·2026
Same author

Precision cancer medicine in Europe: a mixed-methods study on infrastructure for extended molecular diagnostics.

Journal of cancer research and clinical oncology·2026
Same author

Actively expressed microbiota in mucosal biopsies of treatment-naïve ulcerative colitis patients.

Gut microbes reports·2026
Same author

Merging clinical research and standard healthcare - Nordic Precision Cancer Medicine Symposium 2025.

Acta oncologica (Stockholm, Sweden)·2026

Related Experiment Video

Updated: Apr 4, 2026

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
08:20

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

21.9K

High-Throughput Phenotypic Screen to Identify FoxP3 Regulators in Primary T Cells.

Qian Wei1,2, Ehsan Hajjar1, Selma Cornillot-Clément1

  • 1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo 0424, Norway.

ACS Chemical Biology
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Researchers developed a new screening method to find small molecules that specifically target FoxP3, a key regulator in regulatory T cells (Tregs). This approach identifies potential therapies for autoimmune diseases and cancer by modulating Treg function without broad immune suppression.

More Related Videos

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

25.0K
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

11.7K

Related Experiment Videos

Last Updated: Apr 4, 2026

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
08:20

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

21.9K
Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

25.0K
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

11.7K

Area of Science:

  • Immunology
  • Molecular Biology
  • Drug Discovery

Background:

  • Regulatory T cells (Tregs) are crucial for immune homeostasis, suppressing autoimmunity and antitumor responses.
  • Targeting Tregs is a therapeutic strategy for autoimmune diseases and cancer.
  • Need for specific Treg regulators to avoid off-target effects.

Purpose of the Study:

  • Identify small molecules that specifically target the transcription factor FoxP3.
  • Develop and validate a high-throughput screening assay for FoxP3 regulators.

Main Methods:

  • High-throughput, flow-cytometry-based phenotypic screening of human primary T cells.
  • Automated liquid handling pipeline measuring FoxP3 levels in CD4+ T cells.
  • Data processing pipeline with algorithms for toxicity and autofluorescence filtering.
  • Validation of hit candidates through functional analyses and characterization of chemical analogs.

Main Results:

  • Developed a novel screening assay to identify FoxP3 regulators.
  • Identified approved drugs and chemical analogs that modulate Treg function via FoxP3.
  • Revealed structure-activity relationships for potent FoxP3 regulators.

Conclusions:

  • The novel screening method successfully identifies FoxP3 regulators affecting Treg function.
  • This approach offers a promising strategy for developing targeted therapies for immune-related diseases.
  • Further characterization of identified compounds could lead to new therapeutic agents.